Home » Thought Leadership » Podcasts » Speaking of Access: Pricing fo…

Speaking of Access: Pricing for Uncertain Indications

May 5, 2020


Written by: Andrew Gould

Andrew Gould asks our US payer panel for their expert perspectives surrounding pricing for uncertain future indications.

Focusing on TAZVERIK, the panel discuss management expectations, and also disclose whether the expectations of likelihood for approval is ever conferred with them directly.


Apple Podcasts